Journal History
| 2003 | Marine Drugs was founded at the Ocean University of China. The inaugural issue was released. Marine Drugs was published as a quarterly journal. |
| 2005 | Marine Drugs was indexed by Science Citation Index Expanded (SCIE). |
| 2007 | Marine Drugs was indexed by PubMed. |
| 2010 | Marine Drugs adopted a monthly publication schedule. In the same year, the journal was indexed by Scopus. The 2010 Impact Factor for Marine Drugs increased to 3.471, meaning Marine Drugs had become the leading open access journal in the field of drugs sourced from the maritime environment. |
| 2012 | The 2011 Impact Factor for Marine Drugs increased to 3.854. |
| 2013 | The Impact Factor continued to increase to 3.978. Marine Drugs was ranked 6/59 in the “Medicinal Chemistry” Category of Web of Science–Journal Citation Report. Marine Drugs launched its Best Paper Award. Marine Drugs sponsored the 14th International Symposium on Marine Natural Products (MANAPRO 2013). |
| 2014 | The Impact Factor for Marine Drugs was 3.512, and Marine Drugs was ranked 10/58 in the “Medicinal Chemistry” Category of Web of Science–Journal Citation Report. Marine Drugs sponsored the 2014 Gordon Research Conference on Marine Natural Products and the 2014 Oceans & Human Health Gordon Research Conference. |
| 2015 | The Impact Factor for Marine Drugs was 2.853, and Marine Drugs was ranked 22/59 in the “Medicinal Chemistry” Category of Web of Science–Journal Citation Report. Marine Drugs sponsored and collaborated with more conferences, including the 9th European Conference on Marine Natural Products, the 1st Congress of Marine Fungal Natural Products Consortium, the 2015 Gordon Research Conference in Heterocyclic Compounds, and the 1st Sino-Italian symposium on Natural Products. It also built a relationship with TASCMAR (an EU project). Marine Drugs also created its Twitter account. |
| 2016 | The Impact Factor for Marine Drugs increased to 3.345, and the journal ranked 13/59 in the “Medicinal Chemistry” Category of Web of Science–Journal Citation Report. Marine Drugs announced the first edition of the Young Investigator Award. |
| 2017 | The Impact Factor for Marine Drugs increased to 3.503, ranked 13/60 in the “Medicinal Chemistry” Category of Web of Science–Journal Citation Report. |
| 2018 | The Impact Factor for Marine Drugs increased to 4.379, ranked 5/59 in the “Medicinal Chemistry” Category of Web of Science–Journal Citation Report. |
| 2019 | The Impact Factor for Marine Drugs was 3.772, ranked 15/61 (Q1) in the “Medicinal Chemistry” Category of Web of Science–Journal Citation Report. |
| 2020 | The Impact Factor for Marine Drugs increased to 4.073. The CiteScore was 5.1. Marine Drugs became an affiliated journal of The Australia New Zealand Marine Biotechnology Society (ANZMBS). |
| 2021 | The Impact Factor for Marine Drugs increased to 5.118, ranked 12/62 (Q1) in the “Medicinal Chemistry” Category and 60/276 (Q1) in the “Pharmacology & Pharmacy” Category (newly added this year) of Web of Science–Journal Citation Report. The CiteScore for the journal increased to 6.4 in Scopus and placed in the 86% percentile in the Category “Pharmacology, Toxicology and Pharmaceutics (miscellaneous)” (newly added this year), 83% in “Pharmaceutical Science” (newly added this year), and 78% in “Drug Discovery” (newly added this year). |
| 2022 | The Impact Factor increased to 6.085 in the Journal Citation Reports/Science Edition (Clarivate Analytics), and placed in the Q1 quartile in both the “Chemistry, Medicinal” (10/63) and “Pharmacology & Pharmacy” (48/279) Categories. The CiteScore increased to 8.1 in Scopus, and the percentile was 88% in Category “Pharmacology, Toxicology and Pharmaceutics (miscellaneous)”, 86% in “Pharmaceutical Science”, and 82% in “Drug Discovery”. The journal established eight new sections:
|
Editor-in-Chief
| 2003–2005 | Editor-in-Chief: Prof. Dr. Hua-Shi Guan |
| 2005–2009 | Editor-in-Chief: Prof. Dr. Peter Proksch |
| 2009–2013 | Editor-in-Chief: Prof. Dr. Hartmut Laatsch |
| 2014–2018 | Editor-in-Chief: Prof. Dr. Alejandro M. Mayer |
| 2018–2022 | Editor-in-Chief: Prof. Dr. Orazio Taglialatela-Scafati |
| 2022–present | Editor-in-Chief: Prof. Dr. Bill J. Baker |
Section Editor-in-Chief
| 2022 | Section Editor-in-Cheif: Prof. Dr. Bill J. Baker for the Section on Marine Toxins |
| 2022–present | Section Editor-in-Cheif: Prof. Dr. Anake Kijjoa for the Section on Structural Studies on Marine Natural Products Section Editor-in-Cheif: Prof. Dr. Vassilios Roussis for the Section on Marine Chemoecology for Drug Discovery Section Editor-in-Cheif: Prof. Dr. Marialuisa Menna for the Section on Synthesis and Medicinal Chemistry of Marine Natural Products Section Editor-in-Cheif: Prof. Dr. Marc Diederich for the Section on Marine Pharmacology Section Editor-in-Cheif: Prof. Dr. Hermann Ehrlich for the Section on Biomaterials of Marine Origin Section Editor-in-Cheif: Prof. Dr. Yue-Wei Guo for the Section on Marine-Derived Ingredients for Drugs, Cosmeceuticals and Nutraceuticals Section Editor-in-Cheif: Dr. Ipek Kurtboke for the Section on Marine Biotechnology Related to Drug Discovery or Production Section Editor-in-Cheif: Dr. Andrew Turner for the Section on Marine Toxins |
